World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
70
Citations
18714
World Ranking
2406
National Ranking
1155

Medicine

D-Index
72
Citations
19089
World Ranking
19833
National Ranking
9880

Richard B. Pollard publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Richard B. Pollard sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 333 publications — 70th percentile

70% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Richard B. Pollard D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Richard B. Pollard sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 70 D-Index — 52nd percentile

52% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Richard B. Pollard is affiliated with the University of California, Davis in the United States. Their research primarily focuses on the fields of Medicine and Immunology and Microbiology, with particular expertise in Infectious Diseases, Virology, Emergency Medicine, and Epidemiology.

The scientist's research topics concentrate largely on HIV and related conditions. These include:

  • HIV Research and Treatment
  • HIV/AIDS drug development and treatment
  • HIV/AIDS Research and Interventions
  • HIV-related health complications and treatments
  • Pneumocystis jirovecii pneumonia detection and treatment

Richard B. Pollard has authored several papers within these thematic areas, mainly published through UNC Libraries. Recent publications include:

  • Comparison of Sequential Three-Drug Regimens as Initial Therapy for HIV-1 Infection (2020) in UNC Libraries
  • Effects of Combined CCR5/Integrase Inhibitors-Based Regimen on Mucosal Immunity in HIV-Infected Patients Naïve to Antiretroviral Therapy: A Pilot Randomized Trial (2020) in UNC Libraries
  • Proteinuria, CrCl, and Immune Activation in Antiretroviral-Naïve HIV-Infected Subjects (2020) in UNC Libraries
  • Older HIV-infected patients on antiretroviral therapy have B-cell expansion and attenuated CD4 cell increases with immune activation reduction (2020) in UNC Libraries

Collaboration is a significant aspect of their research activity. Frequent co-authors associated with Richard B. Pollard include:

  • Gregory K. Robbins
  • Alan Landay
  • Robert C. Kalayjian
  • Victor De Gruttola
  • Robert W. Shafer

Richard B. Pollard's contributions focus on understanding HIV infection dynamics, treatment regimens, immune system interactions, and related infectious diseases. The combination of published work and interdisciplinary collaboration reflects an engagement with ongoing developments in HIV/AIDS therapies and immunological responses.

Best Publications

  • Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial

    Jeffrey L. Lennox;Edwin DeJesus;Adriano Lazzarin;Richard B. Pollard

  • Effect of Human Leukocyte Interferon on Hepatitis B Virus Infection in Patients with Chronic Active Hepatitis

    Harry B. Greenberg;Richard B. Pollard;Larry I. Lutwick;Peter B. Gregory

  • Sex differences in the Toll-like receptor–mediated response of plasmacytoid dendritic cells to HIV-1

    Angela Meier;J Judy Chang;Ellen S Chan;Richard B Pollard

  • Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy.

    Mark A. Jacobson;Michael Zegans;Michael Zegans;Peter R. Pavan;James J. O'Donnell

  • Comparison of Sequential Three-Drug Regimens as Initial Therapy for HIV-1 Infection

    Gregory K. Robbins;Victor De Gruttola;Robert W. Shafer;Laura M. Smeaton

  • Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection

    Craig W. Hendrix;Ann C. Collier;Michael Marcel Lederman;Dominique Schols

  • Human leukocyte Interferon for the treatment of herpes zoster in patients with cancer.

    Thomas C. Merigan;Kenneth H. Rand;Richard B. Pollard;Paul S. Abdallah

  • Lamotrigine for HIV-associated painful sensory neuropathies: a placebo-controlled trial.

    David M. Simpson;J. C. McArthur;R. Olney;D. Clifford

  • Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group Study

    David W. Haas;Laura M. Smeaton;Robert W. Shafer;Gregory K. Robbins

  • Cytomegalovirus Immune Plasma in Bone Marrow Transplant Recipients

    Drew J. Winston;Richard B. Pollard;Winston G. Ho;James G. Gallagher

  • Incomplete Reconstitution of T Cell Subsets on Combination Antiretroviral Therapy in the AIDS Clinical Trials Group Protocol 384

    Gregory K. Robbins;John G. Spritzler;Ellen S. Chan;David M. Asmuth

  • Increased Pulmonary Superinfections in Cardiac-Transplant Patients Undergoing Primary Cytomegalovirus Infection

    Kenneth H. Rand;Richard B. Pollard;Thomas C. Merigan

  • Safety profile of nevirapine, a nonnucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus infection

    Richard B. Pollard;Patrick Robinson;Kevin Dransfield

  • Mucosal immune responses to HIV-1 in elite controllers: a potential correlate of immune control.

    April L. Ferre;Peter W. Hunt;J. William Critchfield;Delandy H. Young

  • Antiviral treatment of chronic hepatitis B virus infection. I. Changes in viral markers with interferon combined with adenine arabinoside.

    G. H. Scullard;Richard B Pollard;J. L. Smith;S. L. Sacks

  • Raltegravir Versus Efavirenz Regimens in Treatment-Naive HIV-1-Infected Patients: 96-Week Efficacy, Durability, Subgroup, Safety, and Metabolic Analyses

    Jeffrey L. Lennox;Edwin DeJesus;Daniel S. Berger;Adriano Lazzarin

  • Cytomegalovirus Retinitis in Immunosuppressed Hosts: II. Ocular Manifestations

    Peter R. Egbert;Richard B. Pollard;James G. Gallagher;Thomas C. Merigan

  • Glycyrrhizin, an active component of licorice roots, reduces morbidity and mortality of mice infected with lethal doses of influenza virus.

    Tokuichiro Utsunomiya;Makiko Kobayashi;Richard B. Pollard;Fujio Suzuki

  • Cellular immunity and herpesvirus infections in cardiac-transplant patients.

    Kenneth H. Rand;Lucille E. Rasmussen;Richard B. Pollard;Ann Arvin

  • A Pathogenic Role of Th2 Cells and Their Cytokine Products on the Pulmonary Metastasis of Murine B16 Melanoma

    Makiko Kobayashi;Hiroyuki Kobayashi;Richard B. Pollard;Fujio Suzuki

  • Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127.

    Marion G. Peters;Janet Andersen;Patrick Lynch;Tun Liu

  • Effect of baseline- and treatment-related factors on immunologic recovery after initiation of antiretroviral therapy in HIV-1-positive subjects: results from ACTG 384.

    Rajesh T. Gandhi;John Spritzler;Ellen Chan;David M. Asmuth

  • Age-Related Immune Dysfunction in Health and in Human Immunodeficiency Virus (HIV) Disease: Association of Age and HIV Infection with Naive CD8+ Cell Depletion, Reduced Expression of CD28 on CD8+ Cells, and Reduced Thymic Volumes

    Robert C Kalayjian;Robert C Kalayjian;Alan Landay;Richard B. Pollard;Dennis D. Taub

Frequent Co-Authors

Thomas C. Merigan
Thomas C. Merigan Stanford University
David N. Herndon
David N. Herndon The University of Texas Medical Branch at Galveston
Alan L. Landay
Alan L. Landay The University of Texas Medical Branch at Galveston
Michael M. Lederman
Michael M. Lederman Case Western Reserve University
Christopher J. Miller
Christopher J. Miller University of California, Davis
Ronald T. Mitsuyasu
Ronald T. Mitsuyasu University of California, Los Angeles
Margaret A. Fischl
Margaret A. Fischl University of Miami
Ronald J. Bosch
Ronald J. Bosch Harvard University
Robert L. Murphy
Robert L. Murphy Northwestern University
Pablo Tebas
Pablo Tebas University of Pennsylvania

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying Immunology in the USA opens doors to various interdisciplinary career paths, especially in healthcare and research. Many students leverage their immunology background to pursue nursing programs that align with their interest in patient care and disease prevention.

For those looking to enter nursing quickly, exploring options like the easiest absn program to get into can provide a streamlined pathway to becoming a registered nurse. These accelerated programs emphasize efficient admission processes, perfect for fast-tracking your healthcare career.

Alternatively, aspiring nurses can consider lpn programs with easiest admission requirements to begin their clinical journey. Licensed Practical Nurse roles are essential in many medical settings, offering practical experience and foundational knowledge in patient care.

For specialization, the easiest fnp program provides an accessible route to becoming a Family Nurse Practitioner. These programs often balance rigorous academics with flexible admissions, ideal for those focused on family-centered healthcare.

Additionally, if psychiatric care interests you, consider exploring the best psychiatric mental health nurse practitioner programs online. These programs offer strong clinical placements, enhancing your expertise in mental health alongside immunology-related knowledge.

Best Scientists Citing Richard B. Pollard

Trending Scientists

Recently Published Articles